Welcome to Rhogen

Innovative therapeutics in treating life-threatening organ dysfunction

We focus our efforts around developing innovative therapeutic options in treating life-threatening organ dysfunction using recombinant protein fusion technology.

ABOUT RHOGEN

We focus our efforts on the importance and the need for developing successful drug–diagnostic co-development models and bringing us closer towards a more promising future for pharmacotherapy and patient care in treating life-threatening organ dysfunction - Sepsis. We dedicate our efforts around developing innovative therapeutic options in treating life-threatening organ dysfunction using recombinant protein fusion technology.

Area of focus

Sepsis, a life-threatening complication of an infection impacting major organs, is the leading cause of death in hospitalized patients with a mortality rate estimated between 25-35%. is a life-threatening complication of an infection impacting major organs

The growing threat of antimicrobial resistance is a significant challenge to the prevention and successful treatment of sepsis. Delayed, incomplete, and ineffective therapies contribute to the increasing threat of antimicrobial resistance and can increase a patient’s risk for developing sepsis. The rapid-aging population, along with drug-resistant pathogens, have been found to have a higher risk of hospital mortality. Early detection and appropriate treatment of sepsis with pharmacological drugs can decrease mortality, improve patient outcomes, and decrease the length of stay in hospitals.

Our research seeks to validate the role of the enzyme in protecting the host from septic shock caused by bacterial toxin mediated inflammatory response. Our investigation in the role of the recombinant enzyme will expand the current knowledge of innate immunity, provide new insights into inflammatory responses, and importantly, uncover new strategies for the treatment of endotoxin mediated sepsis and septic shock.

Roadmap

At Rhogen, we have developed a roadmap to achieve the desired outcome of innovative therapy to treat the Sepsis. Our illustrative roadmap with an eye towards bringing innovative therapeutic options for the treatment of life-threatening organ dysfunction to the market.

Upcoming Projects

Disease Diagnosis

Early diagnosis is a crucial step in the treatment of Sepsis. The earlier the disease is identified, the better the chances of survival for the patient. We use machine learning technology to diagnose the disease with better accuracy, hours before the onset of severe sepsis. Our artificial intelligence algorithm is novel compared to concurrent techniques since it operates on multimodal patient data from a variety of sources to give a holistic view of accurately predicting the outcome.

Team

Rhogen Biotech

Our team at Rhogen is formed by highly qualified scientists and strategists in the field of developing state of the art predictive models for early diagnosis of sepsis and innovative therapies in addressing the growing needs of the sepsis. In addition, our team relies on a network of knowledge through the advisory board in the medical research and technology, along with successful, commercial, and entrepreneurial experiences.